On tests involving pig skin, the MNPs were capable of penetrating the skin and delivering the vaccine contained in the needles. Produced patches were shown to be shelf-stable for at least six ...

Vaxxas’ proprietary high-density microarray patch (HD-MAP) technology is currently being evaluated in a phase 1 clinical study of the first needle-free COVID-19 vaccine, having demonstrated ...

Vaccines could soon be given by sending plasters in the post, effectively spelling the end of the childhood jab. A landmark trial found the patches — which painlessly penetrate the skin — were ...

3D printed microneedles containing vaccine patches provide a better immune response in patients compared to the vaccination jabs for COVID-19. In terms of antibody responses, the temperature ...

The phase 1/2 randomized trial compared results from the measles and rubella vaccine delivered by a microarray patch, a small sticking plaster-like device with an array of microscopic projections ...

The US$2 million (A$3.2 million) prize will help to accelerate the use of Vaxxas' high-density microarray patch (HD-MAP) technology to administer mRNA vaccines manufactured at UQ's BASE facility.

The selection by BARDA recognizes Vaxxas’ significant advancements towards commercializing its proprietary high-density microarray patch (HD-MAP) for vaccine delivery, including completion of ...

PopVax is developing this vaccine in partnership with Germany’s LTS Lohmann Therapie-Systeme AG (LTS), a leading player in transdermal drug delivery. The Patch Forward Prize is a multi-stage $50 ...